Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 152-157

  Klevay, Michael J ^a   Horn, David L ^b   Neofytos, Dionissios ^c   Pfaller, Michael A ^a   Diekema, Daniel J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal therapy; Candida

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBODY; ANTIFUNGAL AGENT; AZATHIOPRINE; CASPOFUNGIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; RAPAMYCIN; VORICONAZOLE;

ADULT; AGE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; FEMALE; FUNGAL VIRULENCE; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; THERAPEUTIC ERROR; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CASE-CONTROL STUDIES; ECHINOCANDINS; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 67349198886     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.007     Document Type: Article

References (28)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., and Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24 (1997) 1122-1128
2. Alonso-Valle H., Acha O., Garcia-Palomo J.D., Fariñas-Alvarez C., Fernández-Mazarrasa C., and Fariñas M.C. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur. J. Clin. Microbiol. Infect. Dis. 22 (2003) 254-257
3. Anaissie E.J., Karyotakis N.C., Hachem R., Dignani M.C., Rex J.H., and Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170 (1994) 384-389
4. Anaissie E.J., Rex J.H., Uzun O., and Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. 104 (1998) 238-245
5. Antoniadou A., Torres H.A., Lewis R.E., Thornby J., Bodey G.P., Tarrand J.P., Han X.Y., Rolston K.V., Safdar A., Raad I.I., and Kontoyiannis D.P. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82 (2003) 309-321
6. Bertagnolio S., de Gaetano Donati K., Tacconelli E., Scoppettuolo G., Posteraro B., Fadda G., Cauda R., and Tumbarello M. Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors, and predictors of outcome. J. Chemother. 16 (2004) 172-178
7. Cheng Y.R., Lin L.C., Young T.G., Liu C.E., Chen C.H., and Tsay R.W. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J. Microbiol. Immunol. Infect. 39 (2006) 155-161
8. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-Third Edition, M27-A3. (2008), CLSI, Wayne, PA
9. Diekema D.J., and Pfaller M.A. Nosocomial candidemia: An ounce of prevention is worth a pound of cure. Infect. Control Hosp. Epidemiol. 25 (2004) 624-626
10. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., and Dunagan W.C. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15 (1992) 414-421
11. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., and Bearden D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43 (2006) 25-31
12. Graybill J.R. Is there a correlation between serum antifungal drug concentration and clinical outcome. J. Infect. 28 suppl (1994) 17-24
13. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., Herwaldt L., Pfaller M., and Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37 (2003) 1172-1177
14. Horn D.L., Fishman J.A., Steinbach W.J., Anaissie E.J., Marr K.A., Olyaei A.J., Pfaller M.A., Weiss M.A., Webster K.M., and Neofytos D. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn. Microbiol. Infect. Dis. 59 (2007) 407-414
15. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
16. Klevay M.J., Ernst E.J., Hollanbaugh J.L., Hollanbaugh J.L., Miller J.G., Pfaller M.A., and Diekema D.J. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn. Microbiol. Infect. Dis. 60 (2008) 273-277
17. Komshian S.V., Uwaydah A.K., Sobel J.D., and Crane L.R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and the evaluation of factors influencing outcome. Rev. Infect. Dis. 11 (1989) 379-390
18. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., and Weber S.G. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob. Agents Chemother. 49 (2005) 4555-4560
19. MacArthur R.D., Miller M., Albertson T., Panacek E., Johnson D., Teoh L., and Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis. 38 (2004) 284-288
20. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. Clin. Infect. Dis. 181 (2000) 309-316
21. Michalopoulos A.S., Geroulanos S., and Mentzelopoulos S.D. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 124 (2003) 2244-2255
22. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49 (2005) 3640-3645
23. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., Edwards J.E., and Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38 (2004) 161-189
24. Pfaller M.A., and Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42 (2004) 4419-4431
25. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20 (2007) 133-163
26. Rex J.H., Pfaller M.A., and Galgiani J.N. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin. Infect. Dis. 24 (1997) 235-247
27. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P., and National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35 (2002) 627-630
28. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39 (2004) 309-317